Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 443-451

  Pagani, Elena ^a   Falcinelli, Sabrina ^a   Pepponi, Rita ^a,c   Turriziani, Mario ^b   Caporaso, Patrizia ^a   Caporali, Simona ^a   Bonmassar, Enzo ^b   D'Atri, Stefania ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Hyperthermia; Melanoma; Mismatch repair; O6 methylguanine DNA methyltransferase; Temozolomide

Indexed keywords

ALKYLATING AGENT; CANCER VACCINE; DACARBAZINE; DRUG DERIVATIVE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ARTICLE; BASE MISPAIRING; CELL PROLIFERATION; DNA METHYLATION; DNA REPAIR; DOSE RESPONSE; DRUG EFFECT; FEVER; HUMAN; IC 50; MELANOMA; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BASE PAIR MISMATCH; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DNA METHYLATION; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEVER; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; SKIN NEOPLASMS;

EID: 34047274111     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Liénard D, Eggermont AM, Kroon BBR, Schraffordt Koops H and Lejeune FJ: Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol 14: 202-209, 1998.
2. Grünhagen DJ, de Wilt JH, van Geel AN and Eggermont AM: Isolated limb perfusion for melanoma patients - a review of its indications and the role of tumour necrosis factor-α. Eur J Surg Oncol 32: 371-380, 2006.
3. Noorda EM, Vrouenraets BC, Nieweg OE and Kroon BBR: Isolated limb perfusion in regional melanoma. Surg Oncol Clin North Am 15: 373-384, 2006.
4. Thompson JF, Kam PC, Waugh RC and Harman CR: Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14: 238-247, 1998.
5. Falk MH and Issels RD: Hyperthermia in oncology. Int J Hyperthermia 17: 1-18, 2001.
6. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R and Schlag PM: Hyperthermia in combined treatment of cancer. Lancet Oncol 3: 487-497, 2002.
7. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R and Riess H: The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43: 33-56, 2002.
8. Eggermont AM, de Wilt JH and ten Hagen TL: Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4: 429-437, 2003.
9. Van der Zee J, Kroon BBR, Nieweg OE, van de Merwe SA and Kampinga HH: Rationale for different approaches to combined melphalan and hyperthermia in regional isolated perfusion. Eur J Cancer 33: 1546-1550, 1997.
10. Vrouenraets BC, Klaase JM, Nieweg OE and Kroon BBR: Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 14: 224-231, 1998.
11. Fraker DL: Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol 5: 173-184, 2004.
12. Clark J, Grabs AJ, Parsons PG, Smithers BM, Addison RS and Roberts MS: Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 4: 365-370, 1994.
13. Zaffaroni N, Villa R, Orlandi L, Vaglini M and Silvestrini R: Effect of hyperthermia on the formation and removal of DNA interstrand cross-links induced by melphalan in primary cultures of human malignant melanoma. Int J Hyperthermia 8: 341-349, 1992.
14. Anderstam B and Harms-Ringdahl M: Relationship between cellular glutathione and hyperthermic toxicity in mammary carcinoma in mice. Int J Radiat Biol 50: 231-240, 1986.
15. cdc2 kinase activity in human melanoma cells. Br J Cancer 74: 1924-1928, 1996.
16. Hettinga JV, Lemstra W, Meijer C, Dam WA, Uges DR, Konings AW, De Vries EG and Kampinga HH: Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. Br J Cancer 75: 1735-1743, 1997.
17. Raaphorst GP, Mao JP and Ng CE: Repair of potentially lethal damage: its inhibition by hyperthermia in two human melanoma cell lines with different radio- and heat sensitivities. Melanoma Res 3: 351-356, 1993.
18. Raaphorst GP, Mao JP and Ng CE: Sublethal radiation damage repair and its inhibition by hyperthermia in two human melanoma cell lines of different radiosensitivities. Melanoma Res 4: 157-161, 1994.
19. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, Newton C, Lunt E, Fizames C and Lavelle F: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852, 1987.
20. Payne MJ, Pratap SE and Middleton MR: Temozolomide in the treatment of solid tumors: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol 53: 241-252, 2005.
21. Li Y and McClay EF: Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 29: 413-426, 2002.
22. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT and Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23: 35-61, 1997.
23. Hansen WK and Kelley MR: Review of mammalian DNA repair and translational implications. J Pharmacol Exp Ther 295: 1-9, 2000.
24. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J and D'Atri S: DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 66: 478-491, 2004.
25. Tentori L and Graziani G: Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med Chem 9: 1285-1301, 2002.
26. 6-alkylguanine by alkyltransferases. Mutat Res 462: 83-100, 2000.
27. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399, 2002.
28. 6-alkylguanine-DNA alkyltransferase. Carcinogenesis 24: 625-635, 2003.
29. 6-benzylguanine and its role in chemotherapy. Clin Cancer Res 3: 837-847, 1997.
30. Jiricny J: The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7: 335-346, 2006.
31. Iyer RR, Pluciennick A, Burdett V and Modrich PL: DNA mismatch repair: functions and mechanisms. Chem Rev 106: 302-323, 2006.
32. 6-methylguanine and the cytotoxicity of methylating agents. Mutat Res 462: 71-82, 2000.
33. Karran P: Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 22: 1931-1937, 2001.
34. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E and Jiricny J: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54: 334-341, 1998.
35. 2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61: 1957-1963, 2001.
36. 2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 23: 8306-8315, 2003.
37. N1 type methylating agents requires the ATR kinase. Gene Dev 18: 1331-1344, 2004.
38. 6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 23: 359-367, 2004.
39. 6-methylguanine. Oncogene (In press).
40. Fishel R: Signaling mismatch repair in cancer. Nat Med 5: 1239-1241, 1999.
41. Fink D, Aebi S and Howell SB: The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4: 1-6, 1998. (Pubitemid 28062870)
42. Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS and Tyler DS: Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg 188: 532-537, 2004. (Pubitemid 39491100)
43. Ko HS, Ueno T, Yoshimoto Y, Soo YJ, Abdel-Wahab OI, Abdel-Wahab Z, Chu E, Pruitt SK, Friedman HS, Dewhirst MW and Tyler DS: Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 12: 289-297, 2006.
44. Golub SH, Hanson DC, Sulit HL, Morton DL, Pellegrino MA and Ferrone S: Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity. J Natl Cancer Inst 56: 167-170, 1976.
45. Alvino E, Marra G, Pagani E, Falcinelli S, Pepponi R, Perrera C, Haider R, Castiglia D, Ferranti G, Bonmassar E, Jiricny J, Zambruno G and D'Atri S: High-frequency microsatellite instability is associated with defective DNA mismatch repair in human melanoma. J Invest Dermatol 118: 79-86, 2002.
46. 6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 304: 661-668, 2003.
47. Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
48. 6-Methylguanine and temozolomide can reverse the resistance to chloroethyl-nitrosureas of a mouse L1210 leukemia. Anticancer Res 11: 115-121, 1991.
49. 6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumour cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosurea. Cancer Chemother Pharmacol 32: 59-63, 1993.
50. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88: 1004-1011, 2003.
51. Dianov GL, Prasad R, Wilson SH and Bohr VA: Role of DNA polymerase beta in the excision step of long patch mammalian base excision repair. J Biol Chem 274: 13741-13743, 1999. (Pubitemid 129518667)
52. + into a nuclear signal. Gene Dev 19: 1951-1967, 2005.
53. Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, De La Rubia G, Oliver J, Rolli V, Ménissier-De Murcia J and De Murcia G: Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 81: 69-75, 1999.
54. Ochs K, Sobol RW, Wilson SH and Kaina B: Cells deficient in DNA polymerase β are hypersensitive to alkylating agent-induced apoptosis and chromosomal breakage. Cancer Res 59: 1544-1551, 1999.
55. Walker LJ, Craig RB, Harris AL and Hickson ID: A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res 22: 4884-4889, 1994.
56. Ménissier de Murcia J, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, Walztinger C, Chambon P and De Murcia G: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 94: 7303-7307, 1997.
57. Raaphorst GP, Yang DP and Ng CE: Effect of protracted mild hyperthermia on polymerase activity in a human melanoma cell line. Int J Hyperthermia 10: 827-834, 1994.
58. Raaphorst GP, Feeley MM, Chu GL and Dewey WC: A comparison of the effect of hyperthermia on DNA polymerase in hamster and human glioma cells. Int J Hyperthermia 9: 303-312, 1993.
59. Robins HI, Jonsson GG, Jacobson EL, Schmitt CL, Cohen JD and Jacobson MK: Effect of hyperthermia in vitro and in vivo on adenine and pyridine nucleotide pools in human peripheral lymphocytes. Cancer 67: 2096-2102, 1991.
60. Tofilon PJ, Da Silva V, Gutin PH and Deen DF: Effects of hyperthermia on DNA interstrand crosslinking after treatment with BCNU in 9L rat brain tumor cells. Radiat Res 103: 373-382, 1985. (Pubitemid 15017313)
61. Da Silva V, Tofilon PJ, Gutin PH, Dewey WC, Buckley N and Deen DF: Comparative study of the effects of hyperthermia and BCNU on BCNU-sensitive and BCNU-resistant 9L rat brain tumor cells. Radiat Res 103: 363-372, 1985. (Pubitemid 15017312)
62. Bates DA and Mackillop WJ: The effect of hyperthermia on the uptake and cytotoxicity of melphalan in Chinese hamster ovary cells. Int J Radiat Oncol Biol Phys 16: 187-191, 1989.
63. + human tumor cells to N-(2-chloroethyl)-N′-cyclohexyl-N- nitrosourea by mild (41 degrees C) hyperthermia. Cancer Res 48: 1086-1090, 1988.